KEY POINTS
- These GEC-ESTRO consensus recommendations establish standardized target-volume and organ-at-risk (OAR) delineation for rectal endoluminal high-dose-rate brachytherapy (EHB), primarily in curative-intent and organ-preserving treatment. The development process involved 30 experts from 21 centers across nine countries, including 26 radiation oncologists, two medical physicists, one radiation therapist, and one radiologist. Recommendations were developed according to the AGREE II framework using a modified Delphi process, including an institutional practice survey, two expert delineation rounds involving three clinical cases, independent review by four radiation oncologists, and three consensus meetings.
- Substantial variation in existing delineation practice motivated the recommendations. The initial survey, completed by 16 experts from 12 centers, revealed differences in imaging, marker placement, contour definitions, and whether GTV, CTV, HR-CTV, IR-CTV, or PTV structures were used. Most centers relied on CT-based planning, while MRI-based workflows more commonly involved multiple target volumes and additional margins. The consensus therefore established three areas of standardization: prerequisites for accurate delineation, target-volume definitions, and OAR delineation, with a focus on consistent anatomical reporting rather than changing institutional prescription practices.
- Endoscopy and digital rectal examination are central to accurate target localization. Both should be performed before the first applicator placement, with repeat endoscopy advised when the previous examination occurred more than one week before EHB and strongly recommended before each subsequent applicator placement because tumors may regress between fractions. Rigid rectoscopy is preferred when available, and reports should document tumor location using a clock-face orientation (12 o'clock corresponding to the ventral rectal wall), distance from the anal verge, craniocaudal tumor extent, and fiducial positions. Radiopaque markers are recommended for CT- or 2D-guided workflows, generally with up to four markers, while an asymmetric three-marker arrangement may improve applicator-position verification in selected proximal tumors.
- MRI is preferred for treatment planning, but CT remains an acceptable alternative under defined conditions. A recent diagnostic MRI incorporating T2-weighted and diffusion-weighted imaging, preferably acquired within two weeks of EHB, should be available, particularly when planning is CT-based. A pre-imaging enema is strongly recommended, while rectal gel filling should be limited to less than 60 cm³ if used because excessive distension may distort tumor relationships. Planning images must be acquired with the applicator in situ, preferably using MRI; when CT is used, slice thickness should be ≤3 mm, with suitable fiducials and careful consideration of registration uncertainty.
- The primary tumor reporting structure is GTVp_BT, representing macroscopic residual tumor at the time of brachytherapy, principally defined by endoscopy and supplemented by MRI, digital rectal examination, and other available findings. Contiguous extramural vascular invasion and tumor deposits are included, whereas lymph nodes and noncontiguous deposits are excluded from this primary structure. When repeated imaging and replanning are performed, GTVp_BT should be updated to reflect residual tumor at each fraction, with fraction-specific nomenclature such as GTVp_BT1. The consensus also introduces GTVp_BT_ev05, a separate evaluation volume created by expanding GTVp_BT by 5 mm to assess dose to potential microscopic tumor spread. This expansion is for dose reporting only, not a mandatory CTV or prescription margin.
- A separate nodal reporting structure, GTVn_BT, is recommended for residual suspicious disease near the primary tumor. It includes visible remnants of initially suspicious lymph nodes, noncontiguous extramural vascular invasion, and tumor deposits located within 4 cm of GTVp_BT on brachytherapy planning images. These structures are delineated to document incidental or intentional radiation exposure during EHB, although involved lymph nodes are generally treated using EBRT rather than endoluminal brachytherapy. This distinction allows future analyses to evaluate regional dose exposure without implying that EHB should routinely treat nodal disease.
- OAR delineation is organized into standard and exploratory reporting categories, with particular attention to rectal wall exposure and potential late toxicity. OARs should generally be delineated in their entirety when anatomically feasible, except for bowel loops, which need only be contoured within 4 cm of GTVp_BT. The total rectal OAR structure includes the tumor region, while the contralateral rectal mucosa should be represented separately to enable investigation of dose relationships with circumferential fibrosis and strictures. When an organ cannot be completely identified, the visible portion may be contoured using a tilde (~) suffix to indicate incomplete delineation. Crucially, these recommendations do not establish new dose constraints, target prescription margins, or optimal brachytherapy doses, which are intended to be addressed in subsequent guidance.
CLINICAL TAKEAWAY
The GEC-ESTRO consensus provides a standardized framework for defining tumor, nodal, and organ-at-risk structures during rectal endoluminal HDR brachytherapy, supporting reproducible dose reporting and future multicenter comparisons. The recommended 5-mm evaluation expansion should not be interpreted as a mandatory clinical treatment margin, and the guidance does not establish new dose prescriptions or constraints. Its principal value is improving consistency in a specialized organ-preserving treatment technique while enabling future dose-response and toxicity modeling.